Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $4.4200 (-3.28%) ($4.4200 - $4.5700) on Thu. Feb. 17, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.07% (three month average) | RSI | 70 | Latest Price | $4.4200(-3.28%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.9% a day on average for past five trading days. | Weekly Trend | AUTL advances 5.2% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(66%) IBB(61%) IBUY(54%) IWO(53%) ARKG(51%) | Factors Impacting AUTL price | AUTL will decline at least -2.035% in a week (0% probabilities). VIXM(-44%) VXX(-28%) TLT(-24%) TIP(-23%) SHY(-22%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.035% (StdDev 4.07%) | Hourly BBV | -2.5 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $4.49(-1.56%) | 10 Day Moving Average | $4.45(-0.67%) | 20 Day Moving Average | $4.21(4.99%) | To recent high | -35.7% | To recent low | 18.8% | Market Cap | $231m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |